Clinical Trials Logo

Clinical Trial Summary

A Prospective, RanDomized, Multi-Center, Open-Label, Cross-Over Study of Sodium Zirconium Cyclosilicate to Control Interdialytic HyperkalemiA Following Augmentation of Dialysate Potassium: Efficacy to Reduce the Incidence of Post-Dialysis Atrial Fibrillation and Clinically SignificanT Cardiac Arrhythmias - ADAPT Trial


Clinical Trial Description

This is a prospective, open-labelled, randomized, 2x2 cross-over design study of 88 patients with end stage renal disease (ESRD) receiving routine out-patient dialysis using a standard 2.0 potassium ion (K+)/2.5 calcium ion (Ca++) dialysate bath. The overall aim of the study is to determine whether converting stable hemodialysis patients from a "standard" 2.0 K+/2.5 Ca+ dialysate (without Lokelma) to a 3.0 K+/2.5 Ca++ mEq dialysate supplemented with the orally administered potassium binder sodium zirconium cyclosilicate (Lokelma) to treat interdialytic hyperkalemia will reduce the incidence and duration of post-dialysis atrial fibrillation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05535920
Study type Interventional
Source NephroNet, Inc.
Contact Jeremy Whitson, BS
Phone 4239434265
Email jwhitson@nephro-synergy.com
Status Recruiting
Phase Phase 4
Start date April 14, 2022
Completion date June 2023

See also
  Status Clinical Trial Phase
Completed NCT03172702 - Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia Phase 3
Terminated NCT05056727 - A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia Phase 3
Completed NCT02609841 - POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study N/A
Recruiting NCT06277128 - A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia. Phase 2
Recruiting NCT04789239 - OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure Phase 2
Completed NCT05029310 - Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients Phase 4
Terminated NCT04443608 - Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management Phase 4
Completed NCT02607085 - REal World EVidence for TrEAtment of HyperkaLemia in Emergency Department: Multicenter, Prospective, Observational Study N/A
Completed NCT03283267 - A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS) Phase 1
Recruiting NCT06036823 - 5 Versus 10 Units of Insulin in Hyperkalemia Management Phase 4
Recruiting NCT05173584 - Levalbuterol Compared to Albuterol Regarding Cardiac Side Effects and Potassium Lowering Effects. Phase 4
Completed NCT05184998 - Description of the Clinical Outcomes of Hospitalized Patients With Heart Failure With Different Serum Potassium Levels
Completed NCT01737697 - Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia Phase 3
Completed NCT01493024 - Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia Phase 2
Completed NCT04207203 - Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study N/A
Completed NCT05382988 - Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy Phase 3
Completed NCT04217590 - Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects Phase 3
Recruiting NCT03096561 - Measurement of Serum Potassium Rate During Accidental Hypothermia. N/A
Completed NCT03326583 - The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia Phase 2
Completed NCT03528681 - A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia. Phase 3